Lite Strategy (0JW9) Stock Overview

A clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. More details

0JW9 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($25M)

+ 1 more risk

0JW9 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Lite Strategy, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lite Strategy
Historical stock prices
Current Share Price	US$0.76
52 Week High	US$11.26
52 Week Low	US$0.70
Beta	0.044
1 Month Change	-37.38%
3 Month Change	-38.40%
1 Year Change	-66.23%
3 Year Change	-89.61%
5 Year Change	-98.82%
Change since IPO	-98.29%

Recent updates

Shareholder Returns

	0JW9	GB Biotechs	GB Market
7D	-0.2%	-2.8%	1.0%
1Y	-66.2%	17.6%	18.0%

Return vs Industry: 0JW9 underperformed the UK Biotechs industry which returned 17.7% over the past year.

Return vs Market: 0JW9 underperformed the UK Market which returned 18% over the past year.

Price Volatility

Is 0JW9's price volatile compared to industry and market?
0JW9 volatility
0JW9 Average Weekly Movement	9.9%
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.6%
10% most volatile stocks in GB Market	11.8%
10% least volatile stocks in GB Market	3.1%

Stable Share Price: 0JW9's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JW9's weekly volatility has decreased from 15% to 10% over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2000	4	Jay File	www.litestrategy.com

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

Lite Strategy, Inc. Fundamentals Summary

How do Lite Strategy's earnings and revenue compare to its market cap?
0JW9 fundamental statistics
Market cap	US$25.22m
Earnings (TTM)	-US$60.82m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is 0JW9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JW9 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$1.97m
Gross Profit	-US$1.97m
Other Expenses	US$58.85m
Earnings	-US$60.82m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.79
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0JW9 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/14 14:22
End of Day Share Price	2026/06/12 00:00
Earnings	2026/03/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lite Strategy, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Stephen V. Byrne	BofA Global Research
Leah Rush Cann	Brookline Capital Markets
Daniel Brims	Cantor Fitzgerald & Co.

Lite Strategy (0JW9) Stock Overview

Risk Analysis

Lite Strategy, Inc. Competitors

Solvonis Therapeutics

Aptamer Group

Theracryf

Arecor Therapeutics

Price History & Performance

Recent News & Updates

New minor risk - Insider selling

Insider recently sold US$946k worth of stock

Lite Strategy, Inc. (NasdaqCM:LITS) announces an Equity Buyback for $25 million worth of its shares.

New minor risk - Market cap size

New major risk - Shareholder dilution

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Recent updates

New minor risk - Insider selling

Insider recently sold US$946k worth of stock

Lite Strategy, Inc. (NasdaqCM:LITS) announces an Equity Buyback for $25 million worth of its shares.

New minor risk - Market cap size

New major risk - Shareholder dilution

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

MEI Pharma, Inc. announced that it has received $99.999401 million in funding from GSR, Litecoin Foundation Ltd., Mozayyx Management LLC, RLH Capital, LLC, Delta Blockchain Fund LP, CoinFund LLC

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings released: US$2.32 loss per share (vs US$1.31 loss in 3Q 2022)

Insufficient new directors

Insufficient new directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director recently sold US$101k worth of stock

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Revenue beats expectations

Shareholder Returns

Price Volatility

About the Company

Lite Strategy, Inc. Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources